search
Back to results

Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)

Primary Purpose

Hepatocellular Carcinoma

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
neo-TACE-HAIC+Surgery
Surgery alone
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-75 years;
  • BCLC A stage with high-recurrence risk factor;
  • Patients with resectable primary hepatocellular carcinoma;
  • Child-Pugh A or B (7 score) liver function;
  • The volume of residual liver more than 30%

Exclusion Criteria:

  • • With unresectable HCC

    • Pregnant woman or sucking period;
    • With other malignant cancer;
    • Received anti-HCC therapy before this study

Sites / Locations

  • Sun Yat-sen University Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

neo-TACE-HAIC with surgery

surgery alone

Arm Description

transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection

hepatic resection remove the liver tumors

Outcomes

Primary Outcome Measures

Progression-free survival, PFS
PFS was calculated from the date of starting treatment to the date of progression, of disease or death

Secondary Outcome Measures

Overall survival, OS
OS was calculated from the date of starting treatment to the date of death.

Full Information

First Posted
February 28, 2021
Last Updated
February 28, 2021
Sponsor
Sun Yat-sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT04777942
Brief Title
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Official Title
Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With High-risk Barcelona Clinic Liver Cancer (BCLC) A Stage: a Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Recruiting
Study Start Date
February 20, 2021 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although resection was recommend for early stage (BCLC A stage) patients according to the BCLC (Barcelona clinical liver cancer) system, increasing studies suggested that preoperative transarterial therapy may decrease the recurrence risk for those with high-risk factors. However, the clinical value is still undertermined. Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for unresectable HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate. Whether TACE-HAIC would improve survival for BCLC A stage patients with high-risk factors is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
neo-TACE-HAIC with surgery
Arm Type
Experimental
Arm Description
transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
Arm Title
surgery alone
Arm Type
Active Comparator
Arm Description
hepatic resection remove the liver tumors
Intervention Type
Procedure
Intervention Name(s)
neo-TACE-HAIC+Surgery
Intervention Description
transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
Intervention Type
Procedure
Intervention Name(s)
Surgery alone
Intervention Description
hepatic resection remove the liver tumors
Primary Outcome Measure Information:
Title
Progression-free survival, PFS
Description
PFS was calculated from the date of starting treatment to the date of progression, of disease or death
Time Frame
36 months
Secondary Outcome Measure Information:
Title
Overall survival, OS
Description
OS was calculated from the date of starting treatment to the date of death.
Time Frame
60 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-75 years; BCLC A stage with high-recurrence risk factor; Patients with resectable primary hepatocellular carcinoma; Child-Pugh A or B (7 score) liver function; The volume of residual liver more than 30% Exclusion Criteria: • With unresectable HCC Pregnant woman or sucking period; With other malignant cancer; Received anti-HCC therapy before this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiliang Qiu
Phone
862087343114
Email
qiujl@sysucc.org.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Xuzhi Pan
Phone
862087343009
Email
panxzh@sysucc.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yunfei Yuan
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiliang Qiu
Phone
862087343114
Email
qiujl@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Xuzhi Pan
Phone
862087343009
Email
panxzh@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Yunfei Yuan, MD.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)

We'll reach out to this number within 24 hrs